Isomer-selective distribution of 3-n-butylphthalide (NBP) hydroxylated metabolites, 3-hydroxy-NBP and 10-hydroxy-NBP, across the rat blood-brain barrier

Acta Pharmacologica Sinica

Volumn 36, Issue 12, 2015, Pages 1520-1527

  Diao, Xing Xing ^a   Zhong, Kan ^a   Li, Xiu Li ^a   Zhong, Da Fang ^a   Chen, Xiao Yan ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

10 HYDROXY 3 N BUTYLPHTHALIDE; 3 HYDROXY 3 N BUTYLPHTHALIDE; BRAIN PROTEIN; BUTYLPHTHALIDE; PANTOPRAZOLE; TARIQUIDAR; UNCLASSIFIED DRUG; 3-HYDROXY-3-N-BUTYLPHTHALIDE; 3-N-BUTYLPHTHALIDE; BENZOFURAN DERIVATIVE; HERBACEOUS AGENT;

ANIMAL EXPERIMENT; ARTICLE; BLOOD BRAIN BARRIER; BRAIN; BRAIN HOMOGENATE; ISOMER; MALE; NONHUMAN; PARTITION COEFFICIENT; PLASMA; RAT; ANIMAL; BLOOD; ISOMERISM; METABOLISM; ORAL DRUG ADMINISTRATION; SPRAGUE DAWLEY RAT; TRANSPORT AT THE CELLULAR LEVEL;

ADMINISTRATION, ORAL; ANIMALS; BENZOFURANS; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; DRUGS, CHINESE HERBAL; ISOMERISM; MALE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84949230699     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2015.64     Document Type: Article

References (63)

1. Cooke, M. S., Evans, M. D., Dizdaroglu, M. & Lunec, J. Oxidative DNA damage: mechanisms, mutation, and disease. FASEB J 17, 1195-1214 (2003)
2. Wojtovich, A. P. & Foster, T. H. Optogenetic control of ROS production. Redox Biol. 2, 368-376 (2014)
3. Shu, X. et al. A genetically encoded tag for correlated light and electron microscopy of intact cells, tissues, and organisms. PLoS biology 9, e1001041 (2011)
4. Ruiz-Gonzalez, R. et al. Singlet oxygen generation by the genetically encoded tag miniSOG. Journal of the American Chemical Society 135, 9564-9567 (2013)
5. Pimenta, F. M., Jensen, R. L., Breitenbach, T., Etzerodt, M. & Ogilby, P. R. Oxygen-dependent photochemistry and photophysics of miniSOG, a proteinencased flavin. Photochem. Photobiol. 89, 1116-1126 (2013)
6. Qi, Y. B., Garren, E. J., Shu, X., Tsien, R. Y. & Jin, Y. Photo-inducible cell ablation in Caenorhabditis elegans using the genetically encoded singlet oxygen generating protein miniSOG. Proc. Natl Acad. Sci. USA 109, 7499-7504 (2012)
7. Lin, J. Y. et al. Optogenetic inhibition of synaptic release with chromophoreassisted light inactivation (CALI). Neuron 79, 241-253 (2013)
8. Decuyper-Debergh, D., Piette, J. & Van de Vorst, A. Singlet oxygen-induced mutations in M13 lacZ phage DNA. EMBO J 6, 3155-3161 (1987)
9. Sies, H. & Menck, C. F. Singlet oxygen induced DNA damage. Mutat Res. 275, 367-375 (1992)
10. Ooi, S. L., Priess, J. R. & Henikoff, S. Histone H3.3 variant dynamics in the germline of Caenorhabditis elegans. PLoS Genet. 2, e97 (2006)
11. Merritt, C., Rasoloson, D., Ko, D. & Seydoux, G. 3 UTRs are the primary regulators of gene expression in the C. elegans germline. Curr Biol. 18, 1476-1482 (2008)
12. Brenner, S. The genetics of Caenorhabditis elegans. Genetics 77, 71-94 (1974)
13. Loria, P. M., Hodgkin, J. & Hobert, O. A conserved postsynaptic transmembrane protein affecting neuromuscular signaling in Caenorhabditis elegans. J Neurosci. 24, 2191-2201 (2004)
14. Noma, K., Goncharov, A. & Jin, Y. Systematic Analyses of rpm-1 Suppressors Reveal Roles for ESS-2 in mRNA Splicing in Caenorhabditis elegans. Genetics 198, 1101-1115 (2014).
15. Anderson, P. Mutagenesis. Methods Cell Biol. 48, 31-58 (1995)
16. Kutscher, L. M. & Shaham, S. Forward and reverse mutagenesis in C. elegans. (WormBook). The C. elegans Research Community, http://www.wormbook.org 1-26 doi:10.1895/wormbook.1.167.1 (2014)
17. Minevich, G., Park, D. S., Blankenberg, D., Poole, R. J. & Hobert, O. CloudMap: A Cloud-Based Pipeline for Analysis of Mutant Genome Sequences. Genetics 192, 1249-1269 (2012)
18. Denver, D. R. et al. A genome-wide view of Caenorhabditis elegans basesubstitution mutation processes. Proc. Natl Acad. Sci. USA 106, 16310-16314 (2009)
19. Sarin, S. et al. Analysis of multiple ethyl methanesulfonate-mutagenized Caenorhabditis elegans strains by whole-genome sequencing. Genetics 185, 417-430 (2010)
20. Flibotte, S. et al. Whole-genome profiling of mutagenesis in Caenorhabditis elegans. Genetics 185, 431-441 (2010)
21. Spieth, J. & Lawson, D. Overview of gene structure. (WormBook). The C. elegans Research Community, http://www.wormbook.org (2006)
22. Collins, J., Forbes, E. & Anderson, P. The Tc3 family of transposable genetic elements in Caenorhabditis elegans. Genetics 121, 47-55 (1989)
23. Mello, C. & Fire, A. DNA transformation. Methods Cell Biol 48, 451-482 (1995)
24. Mello, C. C., Kramer, J. M., Stinchcomb, D. & Ambros, V. Efficient gene transfer in C. elegans: extrachromosomal maintenance and integration of transforming sequences. EMBO J 10, 3959-3970 (1991)
25. Collins, J., Saari, B. & Anderson, P. Activation of a transposable element in the germ line but not the soma of Caenorhabditis elegans. Nature 328, 726-728 (1987)
26. De Stasio, E. et al. Characterization of revertants of unc-93(e1500) in Caenorhabditis elegans induced by N-ethyl-N-nitrosourea. Genetics 147, 597-608 (1997)
27. Yandell, M. D., Edgar, L. G. & Wood, W. B. Trimethylpsoralen induces small deletion mutations in Caenorhabditis elegans. Proc. Natl Acad. Sci. USA 91, 1381-1385 (1994)
28. Agnez-Lima, L. F. et al. DNA damage by singlet oxygen and cellular protective mechanisms. Mutat Res.. doi:10.1016/j.mrrev.2011.12.005 (2012)
29. Thiviyanathan, V. et al. Base-pairing properties of the oxidized cytosine derivative, 5-hydroxy uracil. Biochemical and biophysical research communications 366, 752-757 (2008)
30. Di Mascio, P., Menck, C. F., Nigro, R. G., Sarasin, A. & Sies, H. Singlet molecular oxygen induced mutagenicity in a mammalian SV40-based shuttle vector. Photochem. Photobiol. 51, 293-298 (1990)
31. Serebrovskaya, E. O. et al. Light-induced blockage of cell division with a chromatin-targeted phototoxic fluorescent protein. Biochem. J 435, 65-71 (2011)
32. Waldeck, W., Mueller, G., Wiessler, M., Toth, K. & Braun, K. Positioning effects of KillerRed inside of cells correlate with DNA strand breaks after activation with visible light. Int. J. Med. Sci. 8, 97-105 (2011)
33. Lan, L. et al. Novel method for site-specific induction of oxidative DNA damage reveals differences in recruitment of repair proteins to heterochromatin and euchromatin. Nucleic Acids Res 42, 2330-2345 (2014)
34. Gavrieli, Y., Sherman, Y. & Ben-Sasson, S.A. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol. 119, 493-501 (1992)
35. Wyman, C. & Kanaar, R. DNA double-strand break repair: alls well that ends well. Annual review of genetics 40, 363-383 (2006)
36. van Schendel, R., Roerink, S. F., Portegijs, V., van den Heuvel, S. & Tijsterman, M. Polymerase Theta is a key driver of genome evolution and of CRISPR/Cas9-mediated mutagenesis. Nat Commun 6, 7394 (2015)
37. McVey, M. & Lee, S. E. MMEJ repair of double-strand breaks (directors cut): deleted sequences and alternative endings. Trends Genet. 24, 529-538 (2008)
38. Frokjaer-Jensen, C. et al. Random and targeted transgene insertion in Caenorhabditis elegans using a modified Mos1 transposon. Nature methods 11, 529-534 (2014)
39. Gibson, D. G. et al. Enzymatic assembly of DNA molecules up to several hundred kilobases. Nature methods 6, 343-345 (2009)
40. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754-1760 (2009)
41. Bigelow, H., Doitsidou, M., Sarin, S. & Hobert, O. MAQGene: software to facilitate C. elegans mutant genome sequence analysis. Nature methods 6, 549 (2009)
42. DePristo, M. A. et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nature genetics 43, 491-498 (2011). 42: 774-81
43. Srikanth CH, Chaira T, Sampathi S, Sreekumar VB, Bambal RB. Correlation of in vitro and in vivo plasma protein binding using ultracentrifugation and UPLC-tandem mass spectrometry. Analyst 2013; 138: 6106-16
44. Zhang F, Xue J, Shao J, Jia L. Compilation of 222 drugs plasma protein binding data and guidance for study designs. Drug Discov Today 2012; 17: 475-85
45. Wan H, Rehngren M, Giordanetto F, Bergstrom F, Tunek A. High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery. J Med Chem 2007; 50: 4606-15
46. Kalvass JC, Maurer TS. Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery. Biopharm Drug Dispos 2002; 23: 327-38
47. Liu X, Chen C. Strategies to optimize brain penetration in drug discovery. Curr Opin Drug Discov Devel 2005; 8: 505-12
48. Kalvass JC, Maurer TS, Pollack GM. Use of plasma and brain unbound fractions to assess the extent of brain distribution of 34 drugs: comparison of unbound concentration ratios to in vivo p-glycoprotein efflux ratios. Drug Metab Dispos 2007; 35: 660-6.
49. Hanada K, Akimoto S, Mitsui K, Mihara K, Ogata H. Enantioselective tissue distribution of the basic drugs disopyramide, flecainide and verapamil in rats: role of plasma protein and tissue phosphatidylserine binding. Pharm Res 1998; 15: 1250-6
50. Takahashi H, Ogata H, Kanno S, Takeuchi H. Plasma protein binding of propranolol enantiomers as a major determinant of their stereoselective tissue distribution in rats. J Pharmacol Exp Ther 1990; 252: 272-8
51. Hammarlund-Udenaes M, Paalzow LK, de Lange EC. Drug equilibration across the blood-brain barrier-pharmacokinetic considerations based on the microdialysis method. Pharm Res 1997; 14: 128-34
52. Shugar ts S, Benet LZ. The rol e of t ranspor ters i n the pharmacokinetics of orally administered drugs. Pharm Res 2009 26 2039-54.
53. Xie Z, Zhang Y, Xu H, Zhong D. Pharmacokinetic differences between pantoprazole enantiomers in rats. Pharm Res 2005; 22: 1678-84
54. Bauer M, Zeitlinger M, Karch R, Matzneller P, Stanek J, Jager W, et al. Pgp-mediated interaction between (R)-[11C]verapamil and tariquidar at the human blood-brain barrier: a comparison with rat data. Clin Pharmacol Ther 2012; 91: 227-33
55. Graber-Maier A, Gutmann H, Drewe J. A new intestinal cell culture model to discriminate the relative contribution of P-gp and BCRP on transport of substrates such as imatinib. Mol Pharm 2010; 7: 1618-28
56. Swift B, Nebot N, Lee JK, Han T, Proctor WR, Thakker DR, et al. Sorafenib hepatobiliary disposition: mechanisms of hepatic uptake and disposition of generated metabolites. Drug Metab Dispos 2013; 41: 1179-86
57. Polli JW, Olson KL, Chism JP, John-Williams LS, Yeager RL, Woodard SM, et al. An unexpected synergist role of P-glycoprotein and breast cancer resistance protein on the central nervous system penetration of the tyrosine kinase inhibitor lapatinib (N-{3-chloro-4-[(3-fluorobenzyl) oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino }methyl)-2-furyl]-4-quinazolinamine; GW572016). Drug Metab Dispos 2009; 37: 439-42
58. Bihorel S, Camenisch G, Lemaire M, Scherrmann JM. Modulation of the brain distribution of imatinib and its metabolites in mice by valspodar, zosuquidar and elacridar. Pharm Res 2007; 24: 1720-8
59. Minocha M, Khurana V, Qin B, Pal D, Mitra AK. Co-administration strategy to enhance brain accumulation of vandetanib by modulating P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp1/Abcg2) mediated efflux with m-TOR inhibitors. Int J Pharm 2012; 434: 306-14
60. Durmus S, Sparidans RW, van Esch A, Wagenaar E, Beijnen JH, Schinkel AH. Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) restrict oral availability and brain accumulation of the PARP inhibitor rucaparib (AG-014699). Pharm Res 2015; 32: 37-46
61. Hillgren KM, Keppler D, Zur AA, Giacomini KM, Stieger B, Cass CE, et al. Emerging transporters of clinical importance: an update from the International Transporter Consortium. Clin Pharmacol Ther 2013; 94: 52-63
62. Russel FG, Koenderink JB, Masereeuw R. Multidrug resistance protein 4 (MRP4/ABCC4): a versatile efflux transporter for drugs and signalling molecules. Trends Pharmacol Sci 2008; 29: 200-7
63. Georgieva JV, Hoekstra D, Zuhorn IS. Smuggling drugs into the brain: an overview of ligands targeting transcytosis for drug delivery across the blood-brain barrier. Pharmaceutics 2014; 6: 557-83